Diego López-Otero, Javier López-Pais, Pablo José Antúnez-Muiños, Carla Cacho-Antonio, Teba González-Ferrero, José Ramón González-Juanatey

Serviço de Cardiologia, Complexo Hospitalar Universitário de Santiago, Santiago de Compostela, A Coruña, Spain
Instituto de Investigación Sanitaria, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, IDICHUS, Santiago de Compostela, A Coruña, Spain
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV) Madrid, Spain

*Corresponding author:
E-mail address: birihh@yahoo.es (D. López-Otero).
Available online 15 August 2020

REFERENCES

Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients

Utilidad y seguridad de la automonitorización electrocardiográfica durante el tratamiento con hidroxicloroquina y azitromicina en pacientes con COVID-19

To the Editor,

Despite the lack of solid evidence on their efficacy, hydroxychloroquine (HCQ) and azithromycin (AZ) have been widely used as a first-line treatment for infection with SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). The effect of these drugs on the QT interval and their potential to cause polymorphic ventricular arrhythmias has generated growing concern in the scientific community and until more robust evidence on their usefulness is available, we must employ strategies to ensure their safe use. Recently, the Food and Drug Administration recommended the use of noninvasive remote monitoring devices to facilitate the monitoring of these patients, which minimizes contact with health care professionals, reduces the burden on health care services and allows more efficient use of resources. To this end, the KardiaMobile 6L device, from AliveCor (California, USA), has been proposed, which can provide a 1- or 6-lead electrocardiogram (ECG), offering a simple and reproducible way to determine the corrected QT interval (QTc). Here in Spain, there are already protocols to support its use in these patients.

During March and April of 2020, a study was conducted in our hospital to analyze the effect of treatment with HCQ (either alone or in combination with AZ) on the QTc and the incidence of ventricular arrhythmias in patients admitted with SARS-CoV-2 pneumonia who met the high-risk criteria for QTc prolongation (female, age > 65 years, history of heart disease, chronic renal disease, or diabetes, or taking both medications together). In line with the recommendations from the experts, a protocol was designed to minimize the arrhythmic complications of these drugs. This protocol included a series of precautions to be taken before and during treatment: a) review what other medications the patient is taking that could prolong the QTc; b) correct electrolyte imbalances; c) avoid bradycardia; and d) perform close electrocardiographic monitoring. A baseline 12-lead ECG was performed on admission. Later, the QTc was monitored using a 6-lead recording taken with the KardiaMobile 6L device, at 48 hours and 96 hours after starting the drugs (or more often if the QTc was > 480 ms, if there was an increase > 60 ms, or if the patient had possible symptoms of arrhythmia). The arrhythmia unit trained the nursing staff responsible for these patients using an informational video on the use of KardiaMobile 6L. After a brief explanation from the nursing staff, the patient performed the
recording, positioning the device on the left knee or ankle (as shown in figure 1). From outside the room, the nurse recorded the ECG on a tablet and transferred it to the electronic medical records. Four electrophysiologists analyzed the recordings and noted in the medical records the details of the ECG, the QTc measurement, and the recommendations on its treatment if they considered it necessary. For patients who were unable to perform the recording themselves, or when the tracing did not allow accurate measurement of the QTc, a 12-lead ECG was performed.

Of 306 patients admitted with COVID-19 pneumonia, 186 received HCQ and met criteria to be considered high risk. Of these, 78 were included in the electrocardiographic monitoring protocol (52 were taking the HCQ plus AZ combination). The baseline QTc was 425 (400-447) ms. Of all the patients, 48 (61.5%) had QTc prolongation on subsequent ECG; 18 (37.5%) were taking HCQ alone and 30 (62.5%) were taking HCQ plus AZ. The baseline characteristics of the study population are shown in table 1, as well as the comparison between the groups with and without prolonged QTc.

No significant differences were found between the patients with and without prolonged QTc. The median QTc prolongation was 25.5 (16.8-57.5) ms, with no significant differences between the groups who were taking HCQ plus AZ and HCQ alone (p = 0.38).

Figure 1. Measurement of the QTc interval on an electrocardiographic recording performed with the KardiaMobile 6L device. QTc, corrected QT interval.
The median QTc duration on monitoring was 450 (436–462) ms. Ten patients (12.8%) had a significant prolongation of the QTc (increase ≥ 60 ms or QTc ≥ 500 ms): 4 (5.1%) were taking HCQ alone and 6 (7.7%) were taking HCQ plus AZ. Five (6.4%) of these patients stopped the medication for this reason. We did not observe sustained ventricular arrhythmia or death due to arrhythmia in any of our patients during the monitoring period. Twelve patients (15.4%) required a conventional ECG due to difficulty interpreting the recording or not being able to use the device due to limited mobility.

According to our experience, HCQ and AZ treatment in patients admitted with COVID-19 is safe as long as measures are taken to minimize the risk of arrhythmia, including close electrocardiographic monitoring. Therefore, given the high burden on the healthcare system caused by this disease, and given its high rate of transmissibility, we think that ECG recording by the patients themselves with devices such as the KardiaMobile 6L can be a simple, useful strategy to avoid unwanted proarrhythmic effects of this treatment.

**Acknowledgements**

This study would not have been possible without the valuable contribution of all the health care professionals involved in the care of our patients with COVID-19. The authors would like to give special thanks to José Luis Ibáñez Criado, Thomas Brouzet, Esperanza Merino de Lucas, Isabel Lillo Ródenas, Vicente Arrarte Esteban, as well as the nurses involved in obtaining the recordings: Eunice González Ríos, Cristina Sogorb Garri, Regina S. Cardoso Monteiro and Norma Pérez Carpio.

**APPENDIX. SUPPLEMENTARY DATA**

Supplementary data associated with this article can be found in the online version available at https://doi.org/10.1016/j.rec.2020.08.020

Amaya García-Fernández, Pablo Ramos-Ruiz, Alicia Ibáñez-Criado, Óscar Moreno-Pérez, Cristina Cambra-Poveda, and Juan Gabriel Martínez-Martínez on behalf of Research Investigation COVID-19 Alicante

**Unidad de Arritmias, Servicio de Cardiología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain**

**Departamento de Endocrinología y Nutrición, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain**

**Departamento de Medicina Clínica, Universidad Miguel Hernández, Elche, Alicante, Spain**
Drug-induced QT prolongation in COVID-19 pneumonia: influence on in-hospital survival

Prolongación del intervalo QT por fármacos en la neumonía por COVID-19: influencia en la supervivencia durante el ingreso

To the Editor,

The COVID-19 pandemic poses an epidemiological challenge and a problem for diagnostic and therapeutic decision-making. The drugs used in patients infected with SARS-CoV-2 have an arrhythmogenic risk associated with QT prolongation, even in patients with a previously normal QT. Recent registries have confirmed that drugs used in patients infected with hydroxychloroquine (HCQ), whether in monotherapy or combination with azithromycin, is associated with significant QT prolongation in COVID-19 patients. However, except in a few reported cases, its association with arrhythmia-related mortality is unclear, and some studies have noted a net neutral effect of these drugs on in-hospital mortality during the treatment of COVID-19 pneumonia, indicating the need for further studies of the arrhythmogenic risk of the treatments used.

Our objective was to determine the changes in QT interval from admission and their relationship with the combinations of drugs used in the treatment of COVID-19 pneumonia. We analyzed 1-month survival according to the degree of QT interval prolongation in the first 48 hours of hospitalization.

We retrospectively included all patients admitted to our center with COVID-19 pneumonia at the start of the pandemic (March 2020) and with available electrocardiogram (ECG) data at baseline and at 48 hours after treatment initiation (performed per protocol in our center). All ECGs were stored in digital format. The Bazett-corrected QT interval (QTc) was measured automatically (DXL ECG Algorithm, TMV, Philips, The Netherlands) and confirmed by 2 independent cardiologists if there was doubt. The at-risk group was defined as patients with long QTc > 60 ms or with a QTc increase (ΔQTc) > 20 ms. Notably, other studies have defined patients with a QTc > 500 ms as being high risk and have recommended precaution with a QTc > 460 ms. We selected a less restrictive cutoff point to permit a stricter follow-up of the at-risk group in order to determine the arrhythmic behavior of patients with COVID-19.

In total, 226 patients were included between March 1 and March 20, 2020. Recruitment was halted when the number of daily admissions impeded an exhaustive follow-up. Finally, 65 patients were excluded due to the lack of a digitalized baseline or 48-hour ECG, leaving 161 patients for the statistical analysis. The most frequently used specific therapeutic regimen was dual therapy with HCQ and lopinavir/ritonavir (LPV/r) (n = 111; 68.9%), followed by triple therapy with HCQ, LPV/r, and azithromycin or a quinolone (n = 30; 18.6%). Monotherapy with azithromycin or LPV/r was the least commonly used strategy (n = 12; 7.5%). Eight patients (5.0%) received alternative combinations.

The drug dosages were similar to those used in other centers. HCQ was administered at 400 mg/12 h in the first 24 hours, followed by 200 mg/12 h. The LPV/r dosage was 400+100 mg/12 h, whereas that of azithromycin was 500 mg/24 h. Categorical variables were compared using the chi-square test and continuous variables using the t test. The survival analysis was an actuarial analysis using the Wilcoxon-Gehan test.

In general, the QTc interval was significantly higher at 48 hours than at admission (443 ± 30 vs 435 ± 25 ms; P < .001), with a mean ΔQTc of 8 ± 28 ms. No significant differences were found in the QTc or in the QTc at 48 hours among the different drug combinations.

Table 1
Baseline characteristics of the study population

<table>
<thead>
<tr>
<th></th>
<th>All (n = 161)</th>
<th>Normal QT group (n = 124)</th>
<th>At-risk QT group (n = 37)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>103 (64)</td>
<td>80 (49.7)</td>
<td>23 (14.3)</td>
<td>.899</td>
</tr>
<tr>
<td>Age, y</td>
<td>63.9 ± 14.8</td>
<td>63.6 ± 15.6</td>
<td>64.7 ± 12.1</td>
<td>.709</td>
</tr>
<tr>
<td>Hypertension</td>
<td>71 (44.1)</td>
<td>52 (32.3)</td>
<td>19 (11.8)</td>
<td>.279</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>25 (15.5)</td>
<td>17 (10.6)</td>
<td>8 (5)</td>
<td>.235</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>57 (35.4)</td>
<td>47 (29.2)</td>
<td>10 (6.2)</td>
<td>.214</td>
</tr>
<tr>
<td>Obesity (BMI &gt; 30)</td>
<td>42 (26.1)</td>
<td>33 (20.5)</td>
<td>9 (5.6)</td>
<td>.785</td>
</tr>
<tr>
<td>COPD/asthma</td>
<td>26 (16.2)</td>
<td>19 (11.8)</td>
<td>7 (4.4)</td>
<td>.591</td>
</tr>
<tr>
<td>Heart disease</td>
<td>26 (16.2)</td>
<td>18 (11.2)</td>
<td>8 (5)</td>
<td>.293</td>
</tr>
</tbody>
</table>

BMI, body mass index; COPD, chronic obstructive pulmonary disease.